New identified biomarker predicts patients who might benefit from HER2-targeted agent

[News]

In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.

More... (https://www.news-medical.net/news/20190222/New-identified-biomarker-predicts-patients-who-might-benefit-from-HER2-targeted-agents.aspx)